Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2017 Oct 4;16(12):2759–2769. doi: 10.1158/1535-7163.MCT-17-0439

Figure 2.

Figure 2

Correlation between activated Notch1 intracellular domain (N1ICD) or cleaved Notch3 and combination index (CI) values for treatment with BMS-906024 and paclitaxel. A, western blot of basal levels of N1ICD and cleaved N3 for all 31 untreated NSCLC cell lines used in the study grouped by KRAS/BRAF status (top: initial set of 14 lines; bottom: additional 17 lines). CI value at the IC50 for paclitaxel and 100 nM BMS-906024 are shown. B, Linear regression of CI values for paclitaxel plus BMS-906024 versus levels of Notch1 ICD normalized to GAPDH in the KRAS and BRAF-WT cell lines. R, Pearson correlation coefficient C, Linear regression of CI values for paclitaxel plus BMS-906024 versus levels of Notch1 ICD normalized to GAPDH in the KRAS or BRAF-mut cell lines. R, Pearson correlation coefficient.